Inventiva (IVA) Cash from Financing Activities (2019 - 2022)
Inventiva (IVA) posted quarterly Cash from Financing Activities of $14.2 million for Q4 2022, up 40038.88% year-over-year from N/an in Q4 2021, and down 2.22% quarter-over-quarter from $14.6 million in Q3 2022.
Inventiva (IVA) Cash from Financing Activities (2019 - 2022) Analysis & Trends
Inventiva's Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $14.2 million for Q4 2022.
- In Q4 2022, Cash from Financing Activities rose 40038.88% year-over-year to $14.2 million; the TTM figure through Dec 2022 stood at $28.9 million (down 1.79% YoY), while the FY2025 annual figure was $280.9 million, up 80.53% from the prior year.
- Cash from Financing Activities for Q4 2022 stood at $14.2 million, down from $14.6 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $29.3 million in Q4 2020, with the low at -$132826.5 in Q4 2019.
- The 4-year median for Cash from Financing Activities is $11.0 million (2020), against an average of $9.5 million.
- The sharpest annual moves came in 2021 and 2022: Cash from Financing Activities tumbled 100.12% in 2021, then surged 40038.88% in 2022.
- Inventiva's Cash from Financing Activities stood at -$132826.5 in 2019, then jumped by 22187.97% to $29.3 million in 2020, then plunged by 99.88% to $35463.1 in 2021, then soared by 40038.88% to $14.2 million in 2022.
- Business Quant data shows IVA's Cash from Financing Activities at $14.2 million in Q4 2022, $14.6 million in Q3 2022, and $35463.1 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Inventiva | 888.89 Mn | 888.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 14.23 Mn |
| Dec 31, 2022 | 14.23 Mn |
| Sep 22, 2022 | 14.56 Mn |
| Sep 22, 2022 | 14.56 Mn |
| Dec 31, 2021 | 35,463.10 |
| Dec 31, 2021 | 35,463.10 |
| Jun 30, 2021 | 56,600.76 |
| Jun 30, 2021 | 56,600.76 |
| Mar 31, 2021 | -19,299.78 |
| Mar 31, 2021 | -19,299.78 |
| Dec 31, 2020 | 29.34 Mn |
| Dec 31, 2020 | 29.34 Mn |
| Jun 30, 2020 | 10.99 Mn |
| Jun 30, 2020 | 10.99 Mn |
| Mar 31, 2020 | 16.15 Mn |
| Mar 31, 2020 | 16.15 Mn |
| Dec 31, 2019 | -132,826.52 |
| Dec 31, 2019 | -132,826.52 |